peptideone
← All peptides

Glucagon

Status unknown

Also known as: Glucagonum, Glucagone, Glukagon Novo, Glucagon, pig, 76LA80IG2G, CHEBI:5391, Glucagon, porcine, for bioassay, Glukagon

Glucagon (Glucagonum, Glucagone, Glukagon Novo) is classified under other / experimental.

What the research says

Aggregated from the cited literature below. We summarize sources — we don't author claims.

Glucagon is a pancreatic alpha-cell–secreted peptide hormone described as an essential regulator of metabolic homeostasis. Research over time has characterized glucagon’s roles in hepatic glucose homeostasis and has expanded glucagon biology to include additional hepatic regulation of lipid and other metabolic pathways. PMIDs: [37367959, 38300523]

Mechanism (as reported)

Research describes glucagon’s hepatic actions in glucose homeostasis and broader metabolic regulation within the hepatocyte, including effects related to fatty acid oxidation, endogenous lipid synthesis, hepatic amino acid metabolism, ketone body metabolism, and mitochondrial turnover/function. PMIDs: [38300523, 37367959]

Key findings (each cites a source)

  • A review reported that glucagon is a peptide hormone secreted from pancreatic alpha cells and is described as an essential regulator of metabolic homeostasis. (PMID: 37367959) [PMID 37367959]
  • Research described glucagon’s ability to promote hepatic glucose production as well characterized, with growing evidence suggesting glucagon is more than a glucose-mobilizing hormone. (PMIDs: 38300523, 37367959) [PMID 38300523, 37367959]
  • A study reported that glucagon action in the liver includes effects consistent with increased fatty acid oxidation and attenuation of endogenous lipid synthesis. (PMID: 38300523) [PMID 38300523]
  • Research reported that glucagon signaling in hepatocytes is implicated in hepatic amino acid and ketone body metabolism and in mitochondrial turnover/function. (PMID: 38300523) [PMID 38300523]
  • A review reported the concept of 'glucagon resistance,' proposing that in individuals with diabetes and fatty liver diseases glucagon’s hepatic actions may be partly impaired, associated with hyperglucagonaemia and related metabolic changes. (PMID: 37367959) [PMID 37367959]
  • A study discussed glucagon receptor agonism (balanced with incretin hormone receptor agonism such as GLP-1) as being developed as a therapeutic target in metabolic diseases like MASLD/MASH, and noted potential links to obesity and chronic kidney disease. (PMID: 38300523) [PMID 38300523]
  • A review reported that mimicry experiments of glucagon signaling have supported development of glucagon receptor antagonists, glucagon receptor agonists, and dual/triple receptor agonists combining glucagon and incretin hormone receptor agonism. (PMID: 37367959) [PMID 37367959]

Independent test grades

No independent third-party test data is available for Glucagon yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.

Research literature (8)

Consolidated from PubMed — each links to the original record.

FAQ

What is Glucagon?
Glucagon (Glucagonum, Glucagone, Glukagon Novo) is classified under other / experimental. Research goals associated with it include metabolic & weight, hormonal & endocrine.
Is Glucagon FDA-approved?
The regulatory status of Glucagon is not established in our sources.
What does the research on Glucagon say?
peptideone aggregates 8 references from PubMed for Glucagon. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.
Aggregated from public sources, with attribution. Not medical advice; compounds discussed are not approved for human consumption. Last updated 2026-06-15.
Glucagon — peptideone